Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-08-30
2011-08-30
Szperka, Michael (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S141100, C424S144100, C514S012200, C514S014300
Reexamination Certificate
active
08007795
ABSTRACT:
The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:FVIIa complex, effectively preventing factor X or FIX binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site. Also provided are humanized antibodies and fragments thereof that bind to the TF.
REFERENCES:
patent: 4644055 (1987-02-01), Kettner et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5122458 (1992-06-01), Post et al.
patent: 5168062 (1992-12-01), Stinski
patent: 5171662 (1992-12-01), Sharma
patent: 5216132 (1993-06-01), Basi
patent: 5223427 (1993-06-01), Edgington et al.
patent: 5225539 (1993-07-01), Winter
patent: 5385839 (1995-01-01), Stinski
patent: 5437864 (1995-08-01), Edgington et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5534254 (1996-07-01), Huston et al.
patent: 5552300 (1996-09-01), Makrides et al.
patent: 5589173 (1996-12-01), O'Brien et al.
patent: 5639641 (1997-06-01), Pedersen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5766886 (1998-06-01), Studnicka et al.
patent: 5861267 (1999-01-01), Su
patent: 5869046 (1999-02-01), Presta et al.
patent: 5879677 (1999-03-01), del Zoppo
patent: 5889157 (1999-03-01), Pastan et al.
patent: 5958713 (1999-09-01), Thastrup et al.
patent: 5985279 (1999-11-01), Waldmann et al.
patent: 5986065 (1999-11-01), Wong et al.
patent: 5997867 (1999-12-01), Waldmann et al.
patent: 6001978 (1999-12-01), Edgington et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6117639 (2000-09-01), Germann et al.
patent: 6245884 (2001-06-01), Hook
patent: 6274142 (2001-08-01), O'Brien et al.
patent: 6287366 (2001-09-01), Derive et al.
patent: 6309636 (2001-10-01), do Couto et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6333167 (2001-12-01), Quinet et al.
patent: 6555319 (2003-04-01), Wong et al.
patent: 6593291 (2003-07-01), Green et al.
patent: 6610293 (2003-08-01), Fischer et al.
patent: 6677436 (2004-01-01), Sato et al.
patent: 6703494 (2004-03-01), Kirchhofer et al.
patent: 6986894 (2006-01-01), O'Brien et al.
patent: 7749498 (2010-07-01), Jiao et al.
patent: 7824677 (2010-11-01), Wong et al.
patent: 2002/0025508 (2002-02-01), Fechteler et al.
patent: 2002/0065327 (2002-05-01), Jiao et al.
patent: 2003/0082636 (2003-05-01), Wong et al.
patent: 2003/0087372 (2003-05-01), DelaCruz et al.
patent: 2003/0109680 (2003-06-01), Wong et al.
patent: 2003/0119075 (2003-06-01), Kirchhofer et al.
patent: 2003/0124117 (2003-07-01), Refino et al.
patent: 2003/0176664 (2003-09-01), Jiao et al.
patent: 2004/0033200 (2004-02-01), Ezban et al.
patent: 2004/0126816 (2004-07-01), Kirchhofer et al.
patent: 2004/0229282 (2004-11-01), Wong et al.
patent: 2005/0089929 (2005-04-01), Jiao et al.
patent: 2005/0271664 (2005-12-01), Wong et al.
patent: 2006/0039901 (2006-02-01), Jiao et al.
patent: 2006/0159675 (2006-07-01), Jiao et al.
patent: 2006/0235209 (2006-10-01), Jiao et al.
patent: 2009/0041766 (2009-02-01), Jiao et al.
patent: 2009/0092602 (2009-04-01), Jiao et al.
patent: 2009/0136501 (2009-05-01), Jiao et al.
patent: 0 239 400 (1987-09-01), None
patent: 0 239 400 (1987-09-01), None
patent: 0 239 400 (1987-09-01), None
patent: 0 420 937 (1991-04-01), None
patent: 1 069 185 (2001-01-01), None
patent: 4-502408 (1992-05-01), None
patent: 1-503438 (1998-11-01), None
patent: 2001-516214 (2001-09-01), None
patent: WO-89/12463 (1989-12-01), None
patent: WO-90/07861 (1990-07-01), None
patent: WO-91/18019 (1991-11-01), None
patent: WO-94/05328 (1994-03-01), None
patent: WO-96/13593 (1996-05-01), None
patent: WO-96/13593 (1996-05-01), None
patent: WO-96/18105 (1996-06-01), None
patent: WO-96/40921 (1996-12-01), None
patent: WO-98/40408 (1998-09-01), None
patent: WO-98/51321 (1998-11-01), None
patent: WO-99/43713 (1999-09-01), None
patent: WO-00/18398 (2000-04-01), None
patent: WO-01/27079 (2001-04-01), None
patent: WO-01/30333 (2001-05-01), None
patent: WO-01/70984 (2001-09-01), None
patent: WO-01/70984 (2001-09-01), None
patent: WO-03/029295 (2003-04-01), None
patent: WO-03/037911 (2003-05-01), None
patent: WO-03/037911 (2003-05-01), None
patent: WO-2005/004793 (2005-01-01), None
patent: WO-2005/004793 (2005-01-01), None
patent: WO-2005/004793 (2005-01-01), None
patent: WO-2005/072126 (2005-08-01), None
patent: WO-2005/072126 (2005-08-01), None
Alberts et al. (2002).The Cell, Garland Science 4thedition, pp. 161, Fig. 3-42.
Albrecht et al. (1992). “An ELISA for Tissue Factor Using Monoclonal Antibodies,”Blood Coagulation and Fibrinolysis3:263-270.
Almus et al. (1990). “Properties of Factor VIIa/Tissue Factor Complexes in an Umbilical Vein Model,”Blood76(2):354-360.
Amirkhosravi et al. (2001).Suppl. To J. of Thrombosis and HaemostasisAbstract: OC1021.
Ardaillou et al. (1992). “Glomerular Tissue Factor Stimulates Thromboxane Synthesis in Human Platelets via Thrombin Generation,”Kidney International41:361-368.
Asadullah, K. et al. (Dec. 1999). “The Pathophysiological Role of Cytokines in Psoriasis,”Drugs of Today35(12):913-924.
Barstad et al. (1995). “Procoagulant Human Monocytes Mediate Tissue Factor/Factor VIIa-Dependent Platelet-Thrombus Formation when Exposed to Flowing Nonanticoagulated Human Blood,”Arteriosclerosis, Thrombosis, and Vascular Biology15(1):11-16 (1995).
Beers et al. (1999).The Merck Manual of Diagnosis and Therapy, 17thedition, Merck Research Laboratories, pp. 1654-1681.
Benedict et al. (Feb. 1995). “Monoclonal Antibody to Tissue Factor Inhibits Intravascular Thrombosis without Impairing Extravascular Hemostasis,”JACCAbstract 1012-1104, p. 366A.
Benhar et al. (1994). “Rapid Humanization of the Fv of Monoclonal Antibody B3 by Using Framework Exchange of the Recombinant Immunotoxin B3(Fv)-PE38,”Proc. Natl. Acad. Sci. USA91:12051-12055.
Bernhard, G.R. et al. (2001). “Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis,”The New England Journal of Medicine344:699-709.
Berzofsky, J.A. et al. (1993). “Immunogenicity and Antigen Structure,” Chapter 8in Fundamental Immunology, Paul, W.E. ed., Raven Press: New York, NY, p. 242.
Bird, R.E. et al. (Oct. 21, 1988). “Single-Chain Antigen-Binding Proteins,”Science242(4877):423-426.
Bjoern et al. (1991). “Human Plasma and Recombinant Factor VII,”The Journal of Biological Chemistry266(17):11051-10057.
Bokarewa et al. (Sep. 2002). “Intra-Articular Tissue Factor/Factor VII Complex Induces Chronic Arthritis,”Inflamm. Res.51(9):471-477.
Booy et al. (2006). “Monoclonal and Bispecific Antibodies as Novel Therapeutics,”Arch. Immunol. Ther. Exp.54:85-101.
Boulianne et al. (1984). “Production of Functional Chimeric Mouse/Human Antibody,”Nature312:643-646.
Broze, G.J., Jr. (1982). “Binding of Human Factor VII and VIIa to Monoytes,”J. Clin. Invest.The American Society for Clinical Investigation, Inc. 70:526-535.
Bruggemann et al. (1989). “The Immunogenicity of Chimeric Antibodies,”J. Exp. Med.170:2153-2157.
Busso, N. et al. (Mar. 2003). “Role of the Tissue Factor Pathway in Synovial Inflammation,”Arthritis Rheum.48(3):651-659.
Cacia et al. (1996). “Isomerization of an Aspartic Acid Residue in the Complementarity-Determining Regions of a Recombinant Antibody to Human IgE: Identification and Effect on Binding Affinity,”Biochemistry35:1897-1903.
Camerer et al. (2000). “Tissue Factor—and Factor X-Dependent Activation of Protease-Activated Receptor 2 by Factor VIIa,”Proc. Natl. Acad. Sci. USA97(10):5255-5260.
Carraway, M.S. et al. (May 1, 2003). “Blockade of Tissue Factor,” Americ
Jiao Jin-An
Mosquera Luis A.
Nieves Esperanza Liliana
Wong Hing C.
Genentech Inc.
Morrison & Foerster / LLP
Szperka Michael
LandOfFree
Anti-tissue factor antibodies and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-tissue factor antibodies and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-tissue factor antibodies and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2765242